RABGEF1

Across TCGA pan-cancer cohorts, RABGEF1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RABGEF1 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RABGEF1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RABGEF1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where RABGEF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.837	0.557	.002	35	view →
PDAC	OS	Tertile	III,IV	0.924	0.525	.003	23	view →
CCRCC	DFS	Quartile	All	0.585	0.879	.003	13	view →
HNSC	DFS	Median	All	0.972	0.913	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RABGEF1–LUAD (DFS)

Open the LUAD breakdown →